Open Access. Powered by Scholars. Published by Universities.®
Articles 1 - 1 of 1
Full-Text Articles in Medical Specialties
A Phase Ii Study Of Acute Toxicity For Celebrex(Tm) (Celecoxib) And Chemoradiation In Patients With Locally Advanced Cervical Cancer: Primary Endpoint Analysis Of Rtog 0128, David K. Gaffney, Kathryn Winter, Adam P. Dicker, Brigitte Miller, Patricia J. Eifel, Janice Ryu, Vilija Avizonis, Mitch Fromm, Kathryn Greven
A Phase Ii Study Of Acute Toxicity For Celebrex(Tm) (Celecoxib) And Chemoradiation In Patients With Locally Advanced Cervical Cancer: Primary Endpoint Analysis Of Rtog 0128, David K. Gaffney, Kathryn Winter, Adam P. Dicker, Brigitte Miller, Patricia J. Eifel, Janice Ryu, Vilija Avizonis, Mitch Fromm, Kathryn Greven
Department of Radiation Oncology Faculty Papers
Purpose: To determine treatment-related acute toxicity rates in patients with locally advanced cervical cancer treated by oral celecoxib, i.v. cisplatin and 5-FU, and concurrent pelvic radiation therapy.
Methods and Materials: Eligible patients on this RTOG Phase I-II study for advanced cervix cancer included FIGO Stage IIB-IVA or patients with FIGO Stage IB through IIA with biopsy proven pelvic node metastases ortumor size >5 cm. Patients were treated with pelvic radiotherapy and brachytherapy. Celecoxib was prescribed at 400 mg twice daily beginning on day 1 for 1 year. Cisplatin (75 mg/m2) and 5-FU (1g/m2 for 4 days) were administered every 3 …